$IBIO
iBio, Inc.

2017 Q4 Form 10-Q Financial Statement

#000114420418009023 Filed on February 14, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q4
Revenue $153.0K $75.00K
YoY Change 104.0% -44.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.590M $2.350M
YoY Change 10.21% 39.88%
% of Gross Profit
Research & Development $993.0K $1.049M
YoY Change -5.34% 49.01%
% of Gross Profit
Depreciation & Amortization $341.0K $326.0K
YoY Change 4.6% 32500.0%
% of Gross Profit
Operating Expenses $3.580M $3.400M
YoY Change 5.29% 42.38%
Operating Profit -$3.427M -$3.325M
YoY Change 3.07% 47.52%
Interest Expense $479.0K $483.0K
YoY Change -0.83%
% of Operating Profit
Other Income/Expense, Net -$473.0K -$467.0K
YoY Change 1.28% -5937.5%
Pretax Income -$3.900M -$3.790M
YoY Change 2.9% 68.44%
Income Tax
% Of Pretax Income
Net Earnings -$3.899M -$3.229M
YoY Change 20.75% 43.77%
Net Earnings / Revenue -2548.37% -4305.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$403.7K -$362.5K
COMMON SHARES
Basic Shares Outstanding 92.82M shares 89.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.310M $16.33M
YoY Change -55.24% 142.64%
Cash & Equivalents $7.310M $16.33M
Short-Term Investments
Other Short-Term Assets $380.0K $290.0K
YoY Change 31.03% 16.0%
Inventory $0.00 $30.00K
Prepaid Expenses
Receivables $140.0K $25.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $7.820M $16.75M
YoY Change -53.31% 132.58%
LONG-TERM ASSETS
Property, Plant & Equipment $25.29M $25.45M
YoY Change -0.64% 181707.14%
Goodwill
YoY Change
Intangibles $1.702M $1.960M
YoY Change -13.16% -10.95%
Long-Term Investments
YoY Change
Other Assets $30.00K $30.00K
YoY Change 0.0%
Total Long-Term Assets $27.02M $27.44M
YoY Change -1.53% 1138.83%
TOTAL ASSETS
Total Short-Term Assets $7.820M $16.75M
Total Long-Term Assets $27.02M $27.44M
Total Assets $34.84M $44.19M
YoY Change -21.16% 369.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $731.0K
YoY Change -4.24% -45.2%
Accrued Expenses $1.130M $905.0K
YoY Change 24.86% 381.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $190.0K $180.0K
YoY Change 5.56%
Total Short-Term Liabilities $2.044M $1.867M
YoY Change 9.48% 21.23%
LONG-TERM LIABILITIES
Long-Term Debt $24.99M $25.18M
YoY Change -0.75%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $24.99M $25.18M
YoY Change -0.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.044M $1.867M
Total Long-Term Liabilities $24.99M $25.18M
Total Liabilities $27.03M $27.04M
YoY Change -0.04% 1658.26%
SHAREHOLDERS EQUITY
Retained Earnings -$63.88M
YoY Change 23.14%
Common Stock $115.0K $68.06M
YoY Change -99.83% 13.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.810M $4.153M
YoY Change
Total Liabilities & Shareholders Equity $34.84M $44.19M
YoY Change -21.16% 369.29%

Cashflow Statement

Concept 2017 Q4 2016 Q4
OPERATING ACTIVITIES
Net Income -$3.899M -$3.229M
YoY Change 20.75% 43.77%
Depreciation, Depletion And Amortization $341.0K $326.0K
YoY Change 4.6% 32500.0%
Cash From Operating Activities -$3.590M -$3.570M
YoY Change 0.56% 115.06%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$170.0K
YoY Change 17.65% -1800.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$200.0K -$170.0K
YoY Change 17.65% -1800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.180M -40.00K
YoY Change -13050.0%
NET CHANGE
Cash From Operating Activities -3.590M -3.570M
Cash From Investing Activities -200.0K -170.0K
Cash From Financing Activities 5.180M -40.00K
Net Change In Cash 1.390M -3.780M
YoY Change -136.77% 129.09%
FREE CASH FLOW
Cash From Operating Activities -$3.590M -$3.570M
Capital Expenditures -$200.0K -$170.0K
Free Cash Flow -$3.390M -$3.400M
YoY Change -0.29% 103.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Minority Interest
MinorityInterest
-1000 USD
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
23000 USD
CY2017Q2 us-gaap Deferred Revenue
DeferredRevenue
157000 USD
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2017Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
26000 USD
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
26000 USD
CY2017Q2 us-gaap Security Deposit
SecurityDeposit
26000 USD
CY2017Q2 us-gaap Minority Interest
MinorityInterest
1000 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7811000 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
190000 USD
CY2017Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
183000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2044000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2013000 USD
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
24985000 USD
CY2017Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
25082000 USD
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96609000 shares
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89109000 shares
CY2017Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000 USD
CY2016Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-563000 USD
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
153000 USD
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
75000 USD
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8915000 USD
CY2016Q4 us-gaap Interest Expense
InterestExpense
483000 USD
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-3900000 USD
CY2017Q4 us-gaap Interest Expense
InterestExpense
479000 USD
CY2017Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.001
CY2017Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.001
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
993000 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1049000 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2587000 USD
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2351000 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
3580000 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
3400000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3427000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3325000 USD
CY2017Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
CY2016Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000 USD
CY2017Q4 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
2000 USD
CY2016Q4 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
4000 USD
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-473000 USD
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-467000 USD
CY2017Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3900000 USD
CY2016Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3792000 USD
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2017Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2016Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2016Q4 us-gaap Profit Loss
ProfitLoss
-3792000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-3229000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-3899000 USD
CY2017Q4 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
65000 USD
CY2016Q4 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0 USD
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3964000 USD
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3229000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
275000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
210000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1978000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1869000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5085000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4820000 USD
us-gaap Operating Expenses
OperatingExpenses
7063000 USD
us-gaap Operating Expenses
OperatingExpenses
6689000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6788000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6479000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
25000 USD
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
16000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-925000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7727000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7404000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
96127000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89109000 shares
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1114000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Interest Expense
InterestExpense
959000 USD
us-gaap Interest Expense
InterestExpense
966000 USD
us-gaap Profit Loss
ProfitLoss
-7727000 USD
us-gaap Profit Loss
ProfitLoss
-7404000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6290000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7725000 USD
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
131000 USD
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6290000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5500000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
394000 USD
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
394000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
506000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
169000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
176000 USD
us-gaap Depreciation
Depreciation
679000 USD
us-gaap Depreciation
Depreciation
650000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-459000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6605000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5837000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
35000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
226000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
277000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
539000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-312000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-765000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6139000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-83000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-778000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6685000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23014000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16329000 USD
ibio Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
22000 USD
ibio Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
197000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
0 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-47000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Interest Paid Net
InterestPaidNet
960000 USD
us-gaap Interest Paid Net
InterestPaidNet
966000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
90000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
83000 USD
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
-26000 USD
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
5000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28000 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0 USD
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-163000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-255000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
206000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-134000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
31000 USD
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
11000 USD
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
0 USD
CY2017Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
2416000 USD
CY2017Q2 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
1805000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
167000 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
99000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.39
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.21
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
138000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.27
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
735000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1702000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1823000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2100000 USD
CY2017Q4 us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
479000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
57225000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
67725000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
2100000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
2100000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
2100000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
2100000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
2100000 USD
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1200000 shares
CY2017Q3 us-gaap Share Price
SharePrice
0.40
CY2016Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4043000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6500000 shares
CY2016Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
241000 USD
CY2017Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
189000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
506000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
394000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13548334 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13555834 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13513517 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11256688 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.34
CY2017Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
200000 USD
ibio Long Term Purchase Commitment Expire Date
LongTermPurchaseCommitmentExpireDate
2015-12-31
CY2017Q4 ibio Revenue From Intersegment
RevenueFromIntersegment
0 USD
CY2017Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
6000 USD
CY2017Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
84000 USD
CY2016Q4 ibio Revenue From Intersegment
RevenueFromIntersegment
0 USD
CY2016Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
16000 USD
CY2016Q4 us-gaap Depreciation
Depreciation
326000 USD
CY2016Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
88000 USD
ibio Revenue From Intersegment
RevenueFromIntersegment
0 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
41000 USD
CY2016Q4 us-gaap Assets
Assets
44188000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25453000 USD
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1960000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
115000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
89000 USD
CY2017Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
83000 USD
CY2017Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
87000 USD
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
911000 USD
CY2017Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
650000 USD
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89118510 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89118510 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
206000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
373000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
445000 USD
CY2016Q4 us-gaap Revenue From Grants
RevenueFromGrants
4000 USD
us-gaap Revenue From Grants
RevenueFromGrants
44000 USD
us-gaap Revenue From Grants
RevenueFromGrants
40000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
321000 USD
us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
1050000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
321000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1050000 USD
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2583000 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1904000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27872000 USD
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27493000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5494000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5446000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
42500 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0223 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0310 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million
ibio Capital Lease Obligation Description
CapitalLeaseObligationDescription
the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMO's applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to approximately $7,000 and $29,000 for the three months ended December 31, 2017 and 2016, respectively, and $24,000 and $45,000 for the six months ended December 31, 2017 and 2016, respectively.
us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
959000 USD
us-gaap Capital Leases Income Statement Interest Expense
CapitalLeasesIncomeStatementInterestExpense
966000 USD
CY2017Q4 ibio Registration Common Stock
RegistrationCommonStock
15000000 USD
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22500000 shares
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.20
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4500000 USD
CY2017Q4 ibio Offering Price To New Investors
OfferingPriceToNewInvestors
0.07 pure
CY2017Q4 ibio Offering Price To Existing Investors
OfferingPriceToExistingInvestors
0.035 pure
CY2017Q4 ibio Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
311000 USD
CY2017Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
ibio Sub Lease Expiration Period
SubLeaseExpirationPeriod
P34Y
CY2017Q4 us-gaap Depreciation
Depreciation
340000 USD
ibio Capital Expenditures Incurred Payments Made
CapitalExpendituresIncurredPaymentsMade
87000 USD
ibio Capital Expenditures Incurred Payments Made
CapitalExpendituresIncurredPaymentsMade
71000 USD
ibio Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
188000 USD
ibio Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
61000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 1.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Nature of Business</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio, Inc. and Subsidiaries (&#8220;iBio&#8221; or the &#8220;Company&#8221;) is a biotechnology company focused on using our proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators and third-party customers as well as developing and commercializing our own product candidates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio was established as a public company in August 2008 as the result of a spin-off from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company's wholly-owned and majority-owned subsidiaries are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>iBIO DO BRASIL BIOFARMAC&#202;UTICA LTDA</b> ("iBio Brazil") &#150; iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company's business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company's existing relationship with Fundacao Oswaldo Cruz/Fiocruz ("Fiocruz") beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>iBio Manufacturing LLC</b> ("iBio Manufacturing") &#150; iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>iBio CDMO LLC</strong> ("iBio CDMO") &#150; iBio CDMO is a Delaware limited liability company formed on December 16, 2015 as iBio CMO, LLC to develop and manufacture plant-made pharmaceuticals. Effective July 1, 2017, iBio CMO changed its name to iBio CDMO. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CDMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (&#8220;Eastern&#8221;), a stockholder of the Company (the &#8220;Eastern Affiliate&#8221;). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CDMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CDMO and contributed a royalty-bearing license which grants iBio CDMO a non-exclusive license to use the Company&#8217;s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company&#8217;s technologies.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company&#8217;s iBio CMO Preferred Tracking Stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share. After giving effect to the transaction, the Company owns <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99.99</font>% of iBio CDMO. See Note 9 for a further discussion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio CDMO&#8217;s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the &#8220;Second Eastern Affiliate&#8221;) as sublandlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font>-square foot Class A life sciences building on the campus of Texas A&#38;;M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CDMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year capital lease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CDMO expects to operate on the basis of three parallel lines of business: (1) development and manufacturing of third-party products; (2) development and production of iBio&#8217;s proprietary product(s) for treatment of fibrotic diseases and/or other proprietary iBio products; and (3) commercial technology transfer services including facility design, as needed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3792000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3623000 USD
ibio Revenue From Intersegment
RevenueFromIntersegment
0 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
20000 USD
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.35 pure

Files In Submission

Name View Source Status
0001144204-18-009023-index-headers.html Edgar Link pending
0001144204-18-009023-index.html Edgar Link pending
0001144204-18-009023.txt Edgar Link pending
0001144204-18-009023-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ibio-20171231.xml Edgar Link completed
ibio-20171231.xsd Edgar Link pending
ibio-20171231_cal.xml Edgar Link unprocessable
ibio-20171231_def.xml Edgar Link unprocessable
ibio-20171231_lab.xml Edgar Link unprocessable
ibio-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv484918_10q.htm Edgar Link pending
tv484918_ex3-2.htm Edgar Link pending
tv484918_ex31-1.htm Edgar Link pending
tv484918_ex31-2.htm Edgar Link pending
tv484918_ex32-1.htm Edgar Link pending
tv484918_ex32-2.htm Edgar Link pending